Letters to the Editor
Preference is given to letters commenting on contributions published recently in the JRSM. The usual length of letters is up to 400 words (one table or illustration may be included) and they should be typed in double spacing.
Spinal complications of ankylosing spondylitis Sir, I read with interest the paper by C H Marsh on the treatment of stress fractures of the ankylosed spine (May 1985 JRSM, p 377) as it raised many interesting points regarding the aetiology, diagnosis and treatment of the spinal complications of longstanding ankylosing spondylitis (AS) on which I would like to comment.
Unfortunately the paper perpetuates several long-standing misconceptions about both Romanus lesions and discovertebral destructive lesions. The two lesions are quite separate entities and are not one and the same as the paper appears to suggest. The Romanus lesion is the inflammatory erosive enthesopathic precursor of the bony syndesmophyte, and as such precedes bony ankylosis'. The painstaking histological studies of Ball have clearly established its inflammatory nature. By comparison, true discovertebral destructive lesions were first described by Andersson in 19372, and are now recognized to be the end result of repeated movement at one isolated mobile spinal segment in an otherwise ankylosed spine3. Such a mobile segment can have many contributing factors, of which a posterior stress fracture is but one element4. Another important cause is isolated non-fusion of the apophyseal joints5. Romanus and Yden in their original article described both true Romanus lesions and discovertebral destructive lesions and postulated that the former may develop into the latter without providing any conclusive radiological or histological evidence.
Secondly, the paper does not particularly emphasize the characteristic clinical features of discovertebral destruction which are very different from the symptoms of an acute exacerbation of AS. Whereas backache caused by the latter is dull, diffuse, localized to the lumbar spine and buttocks, and is eased by exercise, that caused by a destructive lesion is sharp and stabbing, localized to one isolated spinal segment, and is exacerbated by all forms of exercise, including physiotherapy! If such symptoms are observed in the presence of established discovertebral destruction, diagnosis of a mobile segment is relatively straightforward, but some patients exhibit these symptoms in the absence of radiologically evident destructive changes. In such circumstances, a radionuclide bone scan can be of great help, as the scintigraphic appearance of segmental spinal instability is the same whatever its cause, a broad band of isolated increased tracer uptake extending across the entire width of the vertebral column at a level corresponding to the site of localized backache6. Thus skeletal scintigraphy can actually predict potential sites of discovertebral destruction before they occur, and hence prompt treatment by immobilization of the affected segments will actually prevent vertebral destruction6.
At Harlow Wood Orthopaedic Hospital I have now treated 12 patients with AS and such isolated mobile spinal segments by the conservative measures of bed rest until the acute pain has resolved, and immobilization of the affected spinal segment in a rigid spinal brace until body healing of the segment has occurred. In most cases such treatment merely accelerates the natural progression of AS towards complete spinal ankylosis and quickly renders the patient pain-free. I would thus dispute the final conclusion of Marsh's paper which assumes that all such lesions should be treated by surgical means. However, I agree that prompt surgical internal fixation may be the best treatment for a posterior stress fracture, as in my limited experience these lesions are notoriously slow to heal by the conservative measures I have outlined.
Perhaps it is now time for us to abandon the many eponymous and descriptive names that have been attached to the spinal complications of AS and merely call such painful lesions mobile segments, whatever their cause.
*Mr Marsh replies below:
Sir, I am grateful to Dr Dunn for his very well researched and stated comments. It would be most presumptive of me to criticize his conclusions. I must emphasize, however, that it was not my intention to discuss destructive lesions in detail but merely to draw attention to some seemingly trivial but nevertheless disabling stress fractures where no element of destruction was present. He is indeed fortunate that all his patients with painful spinal lesions behaved so courteously and united their 'mobile segments' by conservative means. This, sadly, was not our experience at The Royal National Hospital for Rheumatic Diseases, and failure to improve after extremely long periods was the direct stimulus to perform surgical exploration.
I prefer to think of the rigid spine as a long bone that in itself may suffer stress lesions analogous to those in the tibia, for example, that may be in the anterior or posterior elements. If Dr Dunn had had the benefit of directly observing exposed lesions, I feel that he would agree how ineffective braces and bed rest are in 'immobilizing' a spine: rigid internal fixation has offered an alternative means giving instant relief. Furthermore, despite the stated tendency of a natural progression towards complete spinal ankylosis, in our experience this is not the case in stress fractures or indeed after corrective lumbar osteotomy. These traumatic or surgical defects are notoriously slow to unite despite one's hopes and the presence of rigid internal fixation. All our patients where a destructive lesion could be seen improved spontaneously, though whether this corresponded with a decrease in mobility of the area I cannot say. The opportunity of directly exploring and observing these lesions suggests to me that a very open-minded attitude should be adopted, and pessimism for the chances of spontaneous union allow surgery to be at least considered in resistant cases. I merely offer our experience as a way of avoiding many months of misery in these unfortunate people.
Hospital, Bath
Recombinant human gamma-interferon in primary hepatocellular carcinoma Sir, Dr Forbes and his associates have reported unacceptable toxicity and rapid disease progression in hepatoma patients during treatment with gammainterferon (October 1985 JRSM, p 826). I believe that the unsatisfactory results are probably due to patient selection. Most patients in their study had received previous therapy, had abnormal liver function and were aged over 45. The 2 patients with no history of prior treatment were shown to have distant metastases. All these factors have been shown to be associated with a poor prognosis'. Furthermore, there were too few patients in the study to allow adequate assessment of the response rate at the 95% confidence level2.
The finding of proteinuria in their-patients was interesting; it is possible that the glomerular change was related to the immune complex. The results of renal biopsy with special fluorescent stain would be of interest and perhaps informative.
I believe that the use of recombinant human gamma-interferon in primary hepatoma still requires further assessment, perhaps in a randomized controlled trial. Before doing so, perhaps we might take this opportunity to rectify an error in our paper. The daily dose of IFN'y given was 2.7 x 107 iU m-2, and not 2.7 x 106 as stated, the maximum dose tolerated in the Phase I study having been 3 x iO7 ium-2, not 3 x 106. We apologise for any confusion that this may have caused.
Turning to Dr Shiu's points, it is true that 3 patients had previously received chemotherapy, but as we stated in the results there was no apparent difference in outcome between these and previously untreated patients. The age, presenting biochemistry, and frequency of metastatic disease are typical of patients seen in our unit. Dr Shiu correctly states that the numbers studied were inadequate to assess reponse at the 950% confidence level: we have not claimed otherwise (see introduction and discussion). However, our strong clinical impression was that patients deteriorated more rapidly while on treatment with IFN-y and we would draw attention to the Multifactorial nature of renal impairment in heroin addicts Sir, We read with interest the case report by Gibb and Shaw in the October 1985 issue of the JRSM (p 862) in which they postulate a direct effect of heroin on skeletal muscle causing rhabdomyolysis, myoglobinuria and thus renal failure. We have recently been caring for a 30-year-old heroin abuser who presented with impaired renal function associated with myoglobinuria, but in which other mechanisms needed consideration. Following an overdose of intravenous 'streetheroin' the patient suffered respiratory depression and was ventilated on his way into hospital. Here he recovered so well with naloxone he was able to discharge himself against medical advice. Two days later, after further heroin abuse, he was readmitted in a semiconscious state. Physicalexamination revealed a red, swollen right shoulder. He was pyrexial with a tachycardia and neck stiffness. There were no heart murmurs.
Blood analysis shQwed elevated urea (23.6mmol/l; N 3.0-7.0), creatinine (505 tumol/l; N 80-120) and creatinine phosphokinase (52 QOGIU/l; N 24-195).
Antibody to hepatitis B core antigen was present: the surface antigen was not detected, norf was antibody against HTLV-3. The viscosity was elevated, there was neutrophilia and blood cultures produced a coagulase-negative staphylococcus on one occasion.
Ward testing of urine revealed blood+ + on two occasions but no red blood cells were seen on microscopy. There were large numbers of white cells and casts. Myoglobin was not tested for until day 4 when it was not detected. Renal ultasound showed a nonspecific increase in cortical echogenicity in normal-sized kidneys. Echocardiography showed no evidence of endocarditis. At no time was the patient oliguric. Renal function initially deteriorated but returned to normal by day 15. The plasma creatinine phosphokinase concentration was within normal limits by day 20. A renal biopsy was not performed.
The heroin addict is prone to renal disorders for other reasons besides rhabdomyolysis and myoglobinuria. Glomerular lesions may occur secondary to infection, e.g. hepatitis B, bacterial endocarditis and acquired immune deficiency syndrome', and various histological types of primary glomerulonephritis have been reported2. Ten percent of addicts coming to post-mortem in an American study had chronic glomerulonephritis3. Other mechanisms are amyloid deposition and episodes of hypoxia leading to tubular damage.
Rhabdomyolysis in cases of narcotic overdose has been reported4. In this series 3 of 6 patients presented with painful, swollen muscles. Myoglobinuria was only detected when searched for early. Rhabdomyolysis may be due to pressure necrosis or, as Gibb and Shaw suggest, a direct damaging effect of heroin on muscle.
Our case is consistent with a multifactorial nature of renal impairment in heroin addicts. C FM WESTON DepartmentofMedicine J C CHALKER With respect to the treatment of metastatic prostatic cancer with LHRH analogues (superagonists), he emphasized that drug, dose, route and frequency of administration are very important. He also raised the question of failure to maintain castrate ranges of testosterone throughout a 24-hour period. Faure', whose publication is referred to, refuted this during monotherapy. Data from a Dutch study2 clearly demonstrate that factors like dose, route and frequency may be vital. In contrast to Mr Williams' experience, these other two studies demonstrate that the LHRH analogue buserelin, in the given dose, route and frequency of administration, does not lead to this phenomenon.
Another point we wish to stress is that the LHRH analogues do not cause the disturbing adverse effects seen with oestrogens, e.g. cardiovascular complications or the psychological trauma after orchidectomy. Moreover, their effects are reversed on cessation. Finally, we believe that emphasis on the quality of life in relation to its limited length is of much more importance to a patient with metastatic cancer, as has also been suggested by Brinkley3 and by Guthrie and Maskens4 in the case of ovarian cancer.
D R CHADHA
Medical Department A J VAN T VEEN Hoechst Holland NV, Amsterdam *Mr Williams replies below: Sir, The paper by Faure et al.' that I referred to states quite clearly that in a group of 10 patients treated for periods varying between one and eighteen months, 'blood samples taken eight and twelve hours after the injection of peptide show that each administration of the peptide gave rise to a transient elevation of the steroids'. Table V in this article (page 611) shows a mean serum testosterone of 2.6 ng/ml at two months, which would be out of the castrate range. This reinforces my view that these rises in testosterone and LH are related to the size and frequency of the dose given.
The reference to Faure given by Chadha and van 't Veen is not the one I used.
I also pointed ouit in my editorial that LHRH analogues undoubtedly do have significant advantages over oestrogens with their cardiovascular complications, and over orchidectomy with its inherent psychological problems.
I cannot see any advantage in the reversibility of LHRH analogues after stopping therapy, as this would be a most unlikely situation in somebody with carcinoma of the prostate. 
